SAMUEL RUSSELL: Open Payments
NPI 1902907892 · ELMIRA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,745 in 134 payments from 16 companies in 2025. Trend: 2023 $1,845 · 2024 $2,211 · 2025 $2,745
Food & beverage: $2,745
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 31 | $612 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $471 |
| Regeneron Healthcare Solutions, Inc. | 12 | $314 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 20 | $288 |
| Ardelyx, Inc. | 9 | $265 |
| Madrigal Pharmaceuticals | 13 | $239 |
| Phathom Pharmaceuticals, Inc. | 9 | $138 |
| GENZYME CORPORATION | 3 | $89 |
| Exact Sciences Corporation | 3 | $79 |
| Janssen Biotech, Inc. | 3 | $70 |
Products named: DUPIXENT, ENTYVIO, XIFAXAN, IBSRELA, REZDIFFRA, RINVOQ, LINZESS, VOQUEZNA.
Industry payments across NY — which companies pay providers there.
